Spero Therapeutics, Inc. (SPRO)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Spero Therapeutics, Inc. reported revenue of $66.80M, up 39.2% from the prior year. The company was profitable, with a net margin of 12.8%. It held $68.92M in total assets against $9.90M in total liabilities.
Key ratios (FY2025)
9.5%
Operating margin
12.8%
Net margin
14.5%
Return on equity
+39.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.80M | $47.98M | $103.78M | $53.51M | $18.26M | $9.33M | $18.15M | $3.97M | $1.98M | $335.0K |
| Operating Income | $6.31M | -$73.36M | $21.48M | -$42.20M | -$87.97M | -$79.11M | -$63.22M | -$42.81M | -$41.73M | -$33.22M |
| Net Income | $8.57M | -$68.57M | $22.81M | -$46.41M | -$89.76M | -$78.28M | -$60.92M | -$41.66M | -$39.89M | -$32.64M |
| EPS (Diluted) | $0.15 | $-1.27 | $0.43 | $-1.23 | $-2.91 | — | — | — | — | — |
| Total Assets | $68.92M | $110.54M | $182.39M | $124.80M | $171.07M | $153.45M | $106.10M | $129.01M | $93.48M | $13.77M |
| Total Liabilities | $9.90M | $64.42M | $75.50M | $48.87M | $82.78M | $21.41M | $31.53M | $13.15M | $8.52M | $7.41M |
| Shareholders' Equity | $59.02M | $46.12M | $106.89M | $75.93M | $88.29M | $132.04M | $74.57M | $115.50M | $84.60M | -$45.44M |
| Cash & Equivalents | $40.27M | $52.89M | $76.33M | $109.11M | $112.58M | $85.21M | $29.73M | $34.08M | $87.29M | $10.31M |
| Operating Cash Flow | -$12.62M | -$23.44M | -$32.99M | -$7.73M | -$64.35M | -$85.87M | -$50.02M | -$39.62M | -$39.11M | -$28.96M |
| Capital Expenditures | — | — | — | — | — | $157.0K | $314.0K | $2.44M | $27.0K | $830.0K |
| Shares Outstanding | 56.41M | 54.59M | 53.00M | 52.46M | 32.39M | 29.26M | 19.19M | 17.21M | 14.37M | 0 |